Glenmark partners Evestra to market contraceptive product in US

Glenmark Pharmaceuticals and the US-based Evestra Inc have completed a strategic development, license and commercialisation agreement to develop and market a generic version of Merck & Co’s NuvaRing product - etonogestrel/ethinyl estradiol vaginal ring – designed for women as an effective birth control option.

Development on the vaginal ring product is currently under way and the two companies expect to file an Abbreviated New Drug Application (ANDA) in fiscal 2019.

Evestra will develop this product exclusively for Glenmark for the US market, and will receive certain milestone payments during various stages of the product’s development, including royalties on net sales.

“Bringing high-quality and